BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

NCT06441890 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Paclitaxel
DRUG: Nab-paclitaxel
DRUG: Docetaxel
DRUG: Trastuzumab
DRUG: Pertuzumab

Sponsor

University of Illinois at Chicago